Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti-ror1/Anti-cd3 bispecific binding molecules

A molecular-binding, bispecific technology for anti-receptor/cell surface antigen/cell surface determinant immunoglobulins, anti-animal/human immunoglobulins, antibodies, etc.

Pending Publication Date: 2021-12-31
ВЕЛОСБАЙО ИНК
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Currently, there is no reliable way to antigenically design a single molecule a priori to optimize all these parameters of a bispecific binding molecule, such as an antibody that specifically binds ROR1 and CD3

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-ror1/Anti-cd3 bispecific binding molecules
  • Anti-ror1/Anti-cd3 bispecific binding molecules
  • Anti-ror1/Anti-cd3 bispecific binding molecules

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0671] Example 1: Design and expression of anti-ROR1 / anti-CD3 bispecific binding molecules

[0672] Multiple variables affect the in vivo potency of bispecific binding molecules, including PK, epitope, relative affinities of the binding components, and the valence and steric configuration of the paratope. Currently, there is no reliable way to a priori design a single molecule that optimizes all these parameters. Therefore, multiple anti-ROR1 / anti-CD3 bispecific constructs were designed, fabricated and tested to systematically assess the impact of many of these parameters.

[0673] To identify the structure that provides the optimal conformation, in particular the most active relative spatial position of the ROR1 and CD3 binding components, various constructs were designed, such as figure 1 summed up. Although various bispecific formats have been described (see e.g. Brinkmann and Kontermann, MABS 9:182-212 (2017)), current efforts are focused on formats comprising the Fc com...

Embodiment 2

[0694] Example 2: Binding of anti-ROR1 / anti-CD3 bispecific binding molecules to ROR1

[0695] Bispecific binding molecules with different configurations, ROR1 affinities and ROR1 potencies were evaluated for binding to human ROR1 to determine the effect of these parameters on cytotoxicity. Binding of bispecific constructs 1-20 to human ROR1 was characterized using ROR1 transfected MEC cells, JeKo-1 cells and recombinant ROR1 extracellular domain (ECD).

[0696] Materials and methods

[0697] ROR1 Binding Assay Using Cells and Flow Cytometry

[0698] ROR1 binding was quantified using ROR1-transfected MEC cells and JeKo-1 cells. For each condition, 2.5E5 cells were used. Place cells in 50 μL of PBS with 2% FBS. Cells were then diluted with an equal volume of a 2X stock solution of the test bispecific binding molecule. Co-incubate cells and antibodies on ice for 20 minutes, then wash cells 3 times with 300 μL FACS buffer, resuspend in 100 μL anti-human Fc-PE conjugated ant...

Embodiment 3

[0719] Example 3: Internalization of ROR1 by anti-ROR1 / anti-CD3 bispecific binding molecules

[0720] Internalization and recycling of ROR1 and bispecific binding molecules that recognize ROR1 may affect therapeutic efficacy in vivo. For example, ROR1 binding, internalization, and degradation prior to integration with T cells may reduce cytotoxicity. Anti-ROR1 / anti-CD3 bispecific binding molecules with five different configurations were characterized for binding and internalization.

[0721] While characterizing the internalization of the various bispecific constructs, cell surface expression of ROR1 was detected using two different ROR1 antibodies. One antibody (UC961) recognized the same ROR1 epitope as the bispecific binding molecule, while the other (4A5) recognized a non-overlapping ROR1 epitope.

[0722] In addition, cell surface binding of the bispecific binding molecules was assessed after 24 h incubation at 37°C to determine whether prolonged exposure affected cell ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

This invention relates to bispecific binding molecules that bind to ROR1 and CD3, and methods of using them to treat diseases and conditions such as cancer.

Description

[0001] Cross References to Related Applications [0002] This application claims priority to U.S. Provisional Patent Application 62 / 852,039, filed May 23, 2019. The disclosure of this priority application is incorporated herein by reference in its entirety. [0003] sequence listing [0004] This application contains a Sequence Listing that has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. An electronic copy of the Sequence Listing was created on May 18, 2020, named 024651_WO004_SL.txt, and is 258,844 bytes in size. Background technique [0005] Tyrosine kinase-like orphan receptor 1 (ROR1) is a cell surface protein that mediates signaling from its ligand-secreted glycoprotein Wtn5a. Consistent with its role in influencing stem cell fate during embryogenesis, ROR1 expression is observed in aggressive malignancies that revert to an embryonic transcriptional program but not in normal adult tissues, providing a favorable...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/28
CPCC07K16/2803C07K16/2809C07K2317/31C07K2317/622C07K2317/565C07K2317/55C07K2317/35C07K2317/92C07K2317/70C07K2317/77C07K2317/73C07K2317/624C07K2317/526C07K2317/64A61P35/00A61K2039/505
Inventor J·D·沃特金斯K·杰森M·柯欧B·兰努蒂T-T·沃J·M·沃特金斯
Owner ВЕЛОСБАЙО ИНК
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com